Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Munakata W, Izutsu K, Mishima Y, Nagai H, Ishihara Y, Suzumiya J, Kanakura Y, Nanki T, Miyake T, Kawasaki A, Yoshinaga T, Ishizawa K. Munakata W, et al. Among authors: suzumiya j. Jpn J Clin Oncol. 2023 Oct 4;53(10):912-921. doi: 10.1093/jjco/hyad082. Jpn J Clin Oncol. 2023. PMID: 37486002 Free PMC article. Clinical Trial.
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: suzumiya j. Int J Hematol. 2024 Mar 22. doi: 10.1007/s12185-024-03738-8. Online ahead of print. Int J Hematol. 2024. PMID: 38519820
Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients.
Shimasaki Y, Miyoshi H, Kawamoto K, Yoshida N, Mishina T, Nakashima K, Imamoto T, Sugio T, Yanagida E, Kato T, Yamada K, Takeuchi M, Suzuki T, Moritsubo M, Furuta T, Imaizumi Y, Takizawa J, Kato K, Suzumiya J, Suzuki R, Ohshima K. Shimasaki Y, et al. Among authors: suzumiya j. Cancer Med. 2024 Feb;13(3):e6793. doi: 10.1002/cam4.6793. Epub 2024 Jan 17. Cancer Med. 2024. PMID: 38234210 Free PMC article.
Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
Kato K, Sugio T, Ikeda T, Yoshitsugu K, Miyazaki K, Suzumiya J, Yamamoto G, Kim SW, Ikegame K, Uehara Y, Mori Y, Ishikawa J, Hiramoto N, Eto T, Nakazawa H, Kobayashi H, Serizawa K, Onizuka M, Fukuda T, Atsuta Y, Suzuki R. Kato K, et al. Among authors: suzumiya j. Bone Marrow Transplant. 2024 Mar;59(3):306-314. doi: 10.1038/s41409-023-02156-4. Epub 2023 Dec 15. Bone Marrow Transplant. 2024. PMID: 38102209
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.
Kwak LW, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Menne T, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Ogura M, Kim WS, Lee SJ, Kim SH, Ahn KY, Buske C. Kwak LW, et al. Among authors: suzumiya j. Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):89-97. doi: 10.1016/j.clml.2021.08.005. Epub 2021 Aug 28. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34686445 Free article. Clinical Trial.
289 results